KRAS is a gene that is mutated in many cancers, including around 30% of lung cancers, but no targeted therapies for KRAS-mutant cancers exist yet. Researchers found that blocking two genes that are part of the KRAS signaling pathway, MEK and BCL-XL, using the targeted inhibitors selumetinib (for MEK) and navitoclax (for BCL-XL) shrank tumors in mouse lung cancer models and human tumor samples. While MEK inhibition alone is not effective in KRAS-mutant lung cancer, combining MEK and BCL-XL inhibitors may offer a promising therapeutic approach.


Primary source: